Where can I listen to this podcast?

This podcast is available on 6 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

Rare Diseases Medical Conversation Video

Claim This Podcast

by COR2ED

4.8(4,004 reviews)

10 episodes

Updated Weekly

Accepts GuestsHas SponsorsLocation 🇬🇧

Podcast Overview

Join medical experts as they discuss their approaches to identifying, treating, and managing rare diseases, like primary biliary cholangitis, neuroendocrine tumors, rare bone diseases, and growth disorders. The conversations also explore the evolving treatment landscape, including exciting innovations in gene therapies and the use of somatostatin analogues. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

Language

🇺🇲

Publishing Since

12/6/2023

Visit Website View on Apple Podcasts RSS Feed

1 verified contact email on file for Rare Diseases Medical Conversation Video

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

June 9, 2026

Think narcolepsy: Why early recognition and referral matter in an evolving treatment landscape

Join experts Dr Markus Schmidt and Dr Anna Heidbreder as they discuss the importance of early recognition and referral in narcolepsy type 1 (NT1), particularly as new targeted treatments begin to emerge. Key discussion points include: Emerging therapies: How OX2R agonists may transform narcolepsy care, with Phase 3 overporextin data showing significant improvements in wakefulness and cataplexy with no serious AEs reported. Diagnostic red flags: Recognising excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations to help reduce the current 7–10 year delay in diagnosis. Clinical pitfalls: Avoiding common misdiagnoses, such as attributing symptoms to lifestyle-related fatigue in younger patients or sleep apnoea in older adults. Specialist referral: The importance of timely referral for specialist assessment and objective sleep testing to support earlier access to emerging therapies. By identifying these symptom clusters earlier, clinicians may improve long-term outcomes and quality of life for people living with NT1. Key clinical takeaways: New treatment options are emerging: OX2R agonists represent a shift toward targeting the underlying biology of NT1, with the potential to significantly improve patient outcomes Early recognition is critical: Narcolepsy is often under-recognised and misdiagnosed, so clinicians should maintain a high index of suspicion, particularly in patients with excessive daytime sleepiness Act early and refer appropriately: Timely referral to specialists is essential to confirm diagnosis, optimise management, and ensure patients can benefit from current and emerging therapies You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/sleep-connect/programmes/narcolepsy-early-recognition-referral/?media=0 Or watch on YouTube: https://youtu.be/jHgORhjB_lw Follow us on social media: LinkedIn: https://www.linkedin.com/company/sleep-connect/about/ X: https://x.com/SleepConnect_ Instagram: https://www.instagram.com/cor2edmeded  This content is intended for healthcare professionals only. This podcast is supported by an Independent Education Grant from Takeda This podcast is developed by cor2ed.com Published May 2026 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

November 7, 2025

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers. They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies. Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. Key clinical takeaways: Unlike NETs, EP-NECs are poorly-differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise Accessing a support network can provide emotional reinforcement and information for patients and their care partners You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 Or watch on YouTube: https://youtu.be/nfng2s3jSw8 Follow us on social media: LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true X: https://x.com/net_connectinfo/status/1837039277353382012 This podcast is supported by an Independent Education Grant from ITM. This podcast is developed by cor2ed.com Published in November 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

September 17, 2025

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. Key clinical takeaways: Pair the right patient with the right treatment using an understanding of the key clinical studies The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data The best outcomes are achieved through multi-disciplinary collaborations that include the patient Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0 Follow us on social media: LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true X: https://x.com/net_connectinfo This content is intended for healthcare professionals only. This podcast is supported by an Independent Education Grant from ITM. This podcast is developed by cor2ed.com Published September 2025

10 total episodes available

Deep-dive analytics for Rare Diseases Medical Conversation Video

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Rare Diseases Medical Conversation Video?: Join medical experts as they discuss their approaches to identifying, treating, and managing rare diseases, like primary biliary cholangitis, neuroendocrine tumors, rare bone diseases, and growth disorders. The conversations also explore the evolving treatment landscape, including exciting innovations in gene therapies and the use of somatostatin analogues.

This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
How often does this podcast release new episodes?: This podcast updates weekly.
Where can I listen to this podcast?: This podcast is available on 6 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.